Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astellas Pharma Global Development, Inc.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in 1 or both eyes
Patient with a decision to treat with intravitreal avacincaptad pegol (ACP) prior to enrollment
Patient willingness to complete the patient reported outcome (PRO).
You may not be if
* Active ocular or peri-ocular infection in either eye
* Active, suspected intraocular inflammation in either eye
* Hypersensitive to ACP or to any ingredient in the formulation
Patients currently participating in an investigational program with interventions outside of routine clinical practice.
Patients who have received ACP in the eye being considered for enrollment. Note: Patients who have received or are receiving ACP in the fellow eye at baseline are eligible to be included in the study.
Patients who have received any intravitreal complement inhibitor other than ACP in either eye. Note: Patients who have received an intravitreal complement inhibitor other than ACP in either eye and have completed the 90-day washout period are eligible to be included in the study.
